The mission of the Case CCC Gene Expression &Genotyping Facility (GEGF) is to facilitate implementation of high throughput genetic technologies for the research conducted by members of the CWRU community. The GEGF serves as a technical and consulting resource for Cancer Center members, as well as other investigators laboratories at CWRU, UH, CCF, MHMC and the VAMC, in the areas of high throughput expression analysis and genotyping. It is the only facility of its capability in Cleveland. This Facility utilizes Affymetrix and Applied Biosystems (ABI) technologies as well as Next Generation Sequencing (NGS) to provide global and quantitative (on user-identified genes) gene expression analysis services. While the comprehensive and quantitative properties of NGS assays, for both RNA and DNA, now make these technologies an excellent choice for many genomic studies, these approaches are still very expensive and require extensive informatics expertise for generation of useful data. Therefore, the demand for microarray technology and real time PCR to identify global changes in gene expression and genetic variants in populations has remained at undiminished levels over the past several years. Microarrays have the distinct advantage of providing economical, rapid and readily accessible data that is generically comprehensive in scope, without an overwhelming requirement for computer capacity or informatics expertise. An important service provided by the GEGF, however, is provision of advice to individual investigators on the comparative limits and applicability of the broad range of available technologies for assessment of gene expression and genomic applications. Approximately 60 investigators use the GEGF every year and 30-50% of these are first time users, documenting that the GEGF continues to enjoy a healthy level of growth and a robust level of sustained work with repeat users. Since the last competitive renewal, the Core has provided services for 71 different Cancer Center Members, distributed in all 8 of the Scientific Programs. Part of the impact is through generation of preliminary data and grant support (letters of support;sections of grants;sections for manuscripts;slides for presentations), and the GEGF has played an important role in: determining in vivo targets of the 15-PGDH colon cancer tumor suppressor pathway;identifying CAN genes (Candidate Cancer Genes) in colon cancer;and determining a candidate list of genes involved in conferring resistance or sensitivity to hepatocellular carcinoma in mice fed a high fat diet.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Levinson, Kimberly L; Jernigan, Amelia M; Flocke, Susan A et al. (2016) Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study. J Low Genit Tract Dis 20:47-51
Cooper, Gregory S; Kou, Tzuyung D; Schluchter, Mark D et al. (2016) Changes in Receipt of Cancer Screening in Medicare Beneficiaries Following the Affordable Care Act. J Natl Cancer Inst 108:
Wiechert, Andrew; Saygin, Caner; Thiagarajan, Praveena S et al. (2016) Cisplatin induces stemness in ovarian cancer. Oncotarget 7:30511-22
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2016) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev :
Kenyon, Jonathan; Nickel-Meester, Gabrielle; Qing, Yulan et al. (2016) Epigenetic Loss of MLH1 Expression in Normal Human Hematopoietic Stem Cell Clones is Defined by the Promoter CpG Methylation Pattern Observed by High-Throughput Methylation Specific Sequencing. Int J Stem Cell Res Ther 3:
Dowlati, A; Lipka, M B; McColl, K et al. (2016) Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol 27:642-7
Markowitz, Sanford D; Nock, Nora L; Schmit, Stephanie L et al. (2016) A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS One 11:e0146435
Wang, Y; Deng, O; Feng, Z et al. (2016) RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. Oncogene 35:1363-72
Doherty, Mary R; Smigiel, Jacob M; Junk, Damian J et al. (2016) Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) 8:
Blum, Andrew E; Venkitachalam, Srividya; Guo, Yan et al. (2016) RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res 76:5628-5633

Showing the most recent 10 out of 1148 publications